about
Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- miceCannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosisTargeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosisChronic hypocalcemia of vitamin D deficiency leads to lower intracellular calcium concentrations in rat hepatocytesCannabinoid signaling and liver therapeutics.Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liverThe endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsHepatic fibrosis: molecular mechanisms and drug targets.Endocannabinoids as novel mediators of liver diseases.Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesityEnvironmental factors as disease accelerators during chronic hepatitis C.Cannabinoid receptors as therapeutic targets in the management of liver diseases.Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model.Pathophysiology of NASH: perspectives for a targeted treatment.Endocannabinoids and their role in fatty liver disease.The metabolic syndrome and chronic liver disease.Autophagy: a multifaceted partner in liver fibrosis.Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication.Autophagy in chronic liver diseases: the two faces of Janus.Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin.The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis.Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.Statins Modulate Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 in Human Hepatic Myofibroblasts.Homocysteine decreases endothelin-1 production by cultured human endothelial cells.Macrophage autophagy protects against liver fibrosis in mice.ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.Inhibition of the calcium pump by human parathyroid hormone-(1-34) and human calcitonin in liver plasma membranesPre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness.Inhibition by glucagon of the calcium pump in liver plasma membranes.Role of NF-kappaB in the antiproliferative effect of endothelin-1 and tumor necrosis factor-alpha in human hepatic stellate cells. Involvement of cyclooxygenase-2.Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins.The inhibitor of liver plasma membrane (Ca2+-Mg2+)-ATPase. Purification and identification as a mediator of glucagon action.The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway.M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E2 in Liver Fibrosis Is Associated with Reduced Fibrogenesis.Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors.Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts.
P50
Q28476642-1932EDE5-E8F6-4FE6-A59C-04FBB0007962Q33464957-16CAE7FB-3C84-4046-9346-05B557779347Q33947213-E7E3FC5B-EE15-4F53-9E22-257804174D59Q34145898-4F2A8C35-66D3-4EC0-9EC1-9D3332791310Q34337876-5DA0185C-42D2-4EC1-AB61-0D04DFAC6F51Q34794697-6BF9BD80-0D2E-4CA5-9DCC-E86073C6BC72Q35193292-F4D5D4D4-16B3-4BE1-8CF1-0AA443412352Q35911848-F5ABEDD9-65B1-4FB3-B95E-F1B4046296A7Q36496657-4AC1E7A6-2E2B-492F-B8E3-BC31B0071B1FQ36734955-D5282E2F-5A49-4A6E-BC59-B794938008A4Q37023005-2C8277ED-831C-481B-9CB6-E676E65FA823Q37086429-26DA53BE-6E38-41E6-BA10-8664126DEB99Q37405983-32B8FA4E-D036-4F17-ADE6-72AC94C94092Q37674933-ECC328CD-CDDF-4094-B562-37D046C1926CQ37699476-CA247072-4736-455A-A57D-D53050C97B77Q37749378-A60F7AE3-F598-4036-B753-13FE60E0F73BQ38169739-E2F01533-68AC-44F2-A4E9-E52581AA0160Q38254156-CA858A93-5D79-4B74-8D12-22F958174AFEQ38971509-00291303-485E-4140-9D55-E6506709EE76Q39024897-698FF1FF-044A-45E8-A1BD-3F2CA6974369Q39072337-7CA0AF8B-5B3F-4F9D-BA74-BD99A764243FQ39960326-834DEAA7-880A-48FA-8CDD-37D99B973C58Q40001901-30979376-354B-4B44-8054-BF5430FBEEECQ40419037-F0C44599-21E2-4A1B-A6A7-D6EF6C75E8AFQ40941876-E71020D1-5AC7-4291-A29E-508CD14C1DBEQ41504958-32AE9093-45B5-4BA6-A134-F3B5F7328FE2Q41921041-6DAD4A5B-EE63-43D0-BB9B-AA7214AF8475Q41948101-43FB6A3A-716E-4CD0-950C-4DCE4F441A06Q42339215-BD9866CB-4C90-4E74-97AC-55430FFE7D4FQ42447324-96A832C9-4B44-4489-B23A-8F3B9FDD2C5FQ42460529-950847F4-D78A-408E-AB9B-959F0D1A83DEQ42478873-51A5F5E8-0315-4A5B-AB48-AEFFD5D7DA86Q42513636-22BF35A7-3539-4A5F-9928-8CF1E56CAB31Q42534041-E28A1696-E15E-47ED-AE46-FC94C90AECFAQ42710363-D9CBB8BC-60B9-4186-B382-F4797B4DB746Q42797958-0287AAA3-BF31-4838-A32A-CF18915EBCF7Q43047280-01E8A285-DD7E-4064-B9A1-0C6948046B6FQ43476058-ED313F49-7739-49E2-A797-0B00C2C4DE1BQ43690457-58C254F3-705E-4AE3-A541-DC54853640FEQ44077314-B23C513B-A116-41EF-A5A0-7AE25F468AE0
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@nl
type
label
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@nl
prefLabel
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@nl
P106
P21
P31
P496
0000-0002-0053-7807